Disparities in Diabetes Care: Asian Patients Screened Early but Blocked from Weight-Loss Drugs
A South Asian physician highlights a troubling gap in healthcare: despite being screened for diabetes at a BMI of 23—aligned with guidelines for Asian populations—he was denied access to GLP-1 drugs due to a 30-BMI eligibility threshold. This mismatch reflects broader inequities, as clinical guidelines evolve while insurance coverage tightens. The disconnect underscores how systemic barriers affect high-risk groups even when early detection is prioritized.
A South Asian physician, Dr. Hamayle Saeed, was screened for diabetes at a BMI of 23—aligned with American Diabetes Association (ADA) guidelines for Asian populations—but denied access to GLP-1 weight-loss drugs due to a 30-BMI eligibility threshold. Despite having a BMI of 26.5 and no diabetes, he fell short of the criteria used by insurers and prior authorization forms, which still rely on outdated thresholds despite updated clinical guidance. This disconnect is rooted in historical clinical trial design: pivotal GLP-1 trials used Western BMI cutoffs (30), leading to underrepresentation of Asian participants—only 13.5% of Asian Americans were eligible in one analysis—despite evidence that these drugs work effectively in lower-BMI populations. The 2025 STEP 11 trial in South Korea and Thailand, using a local obesity definition (BMI ≥25), showed significant weight loss even among those below 30 BMI, yet such findings have not translated into coverage changes. Meanwhile, insurers like Medi-Cal and MassHealth have removed GLP-1 coverage for weight management, disproportionately affecting patients with marginal eligibility. The ADA updated its 2026 Standards of Care to recommend ethnicity-specific thresholds, including lower cutoffs for South Asians, but payers have not followed suit. Organizations such as NICE in the UK have incorporated ethnic adjustments into their guidelines, while U.S. systems have not—highlighting a systemic failure to align policy with evolving science. W
This story underscores how medical guidelines can advance while access policies lag, disproportionately impacting high-risk populations already facing structural barriers. Asian Americans, who develop diabetes and cardiovascular disease at lower BMIs, are caught in a system that recognizes their risk clinically but denies them treatment based on outdated metrics. The effect may ripple through healthcare equity, deepening disparities in chronic disease management and increasing long-term costs from preventable complications. Comparable to the 2021 removal of race from eGFR calculations—where eliminating a flawed coefficient improved Black patients’ access to transplants—this case suggests that re-evaluating BMI thresholds could be a necessary correction. However, unlike that reform, which was driven by clear evidence of harm, this issue remains mired in bureaucratic inertia. Insurers may resist change due to cost concerns, even as real-world outcomes show benefit at lower BMIs. What cou